440
Participants
Start Date
March 2, 2017
Primary Completion Date
June 30, 2020
Study Completion Date
April 12, 2021
Ramucirumab
Administered IV
Paclitaxel
Administered IV
Placebo
Administered IV
De La Salle Health Sciences Institute, Cavite City
Cebu Doctors Hospital, Cebu City
Dr. Pablo O. Torre Memorial Hospital, Bacolod
King Chulalongkorn Memoiral Hospsital, Bangkok
Police General Hospital, Bangkok
Rajavithi Hospital, Bangkok
Advanced Medical & Dental Institute HUSM, Kepala Batas, Pulau Pinang
Khon Kaen Hospital, Khon Kaen
Hospital Kuala Lumpur, Kuala Lumpur
University Malaya Medical Centre, Kuala Lumpur
National Cancer Institute, Wilayah Persekutuan
Hospital Umum Sarawak, Kuching
The Fifth Medical Center of PLA General Hospital, Beijing
Beijing Cancer Hospital, Beijing
The First Hospital of China Medical University, Shenyang
Jilin Province Tumor Hospital, Changchun
Harbin Medical University Cancer Hospital, Harbin
Zhongshan Hospital, Fudan University, Shanghai
Nan Jing No. 81 Hospital, Nanjing
Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med, Nanjing
Jiangsu Cancer Hospital, Nanjing
Tianjin Medical University Cancer Institute & Hospital, Tianjin
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
Sir Run Run Shaw Hospital, Hangzhou
Fujian Medical University Union Hospital, Fuzhou
Hunan Cancer Hospital, Changsha
Wuhan Union (Xiehe) Hospital, Wuhan
Wu Han Tongji Hospital, Wuhan
First hospital affiliated to Zhengzhou University, Zhengzhou
Sun Yat-sen University Cancer Center, Guangzhou
Guangdong Provincial People's Hospital, Guangzhou
Tang Du Hospital, The Second Teaching Hospital of FMMU, Xi’an
Eli Lilly and Company
INDUSTRY